The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
出版年份 2012 全文链接
标题
The Molecular Basis of Drug Resistance against Hepatitis C Virus NS3/4A Protease Inhibitors
作者
关键词
-
出版物
PLoS Pathogens
Volume 8, Issue 7, Pages e1002832
出版商
Public Library of Science (PLoS)
发表日期
2012-07-27
DOI
10.1371/journal.ppat.1002832
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Virologic Escape during Danoprevir (ITMN-191/RG7227) Monotherapy Is Hepatitis C Virus Subtype Dependent and Associated with R155K Substitution
- (2011) Sharlene R. Lim et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial
- (2011) Michael Manns et al. ANTIVIRAL THERAPY
- Differential Efficacy of Protease Inhibitors Against HCV Genotypes 2a, 3a, 5a, and 6a NS3/4A Protease Recombinant Viruses
- (2011) Judith M. Gottwein et al. GASTROENTEROLOGY
- An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
- (2011) Marc G. Ghany et al. HEPATOLOGY
- Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
- (2011) Ann D Kwong et al. NATURE BIOTECHNOLOGY
- Boceprevir for Untreated Chronic HCV Genotype 1 Infection
- (2011) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
- (2011) Bruce R. Bacon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Retreatment of HCV Infection
- (2011) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- PHENIX: a comprehensive Python-based system for macromolecular structure solution
- (2010) Paul D. Adams et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Induced-Fit Binding of the Macrocyclic Noncovalent Inhibitor TMC435 to its HCV NS3/NS4A Protease Target
- (2010) Maxwell D. Cummings et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease
- (2010) P. W. White et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435
- (2010) O. Lenz et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors
- (2010) A. Bae et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- 761 IDENTIFICATION AND PRECLINICAL PROFILE OF THE NOVEL HCV NS3 PROTEASE INHIBITOR BMS-650032
- (2010) F. McPhee JOURNAL OF HEPATOLOGY
- Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection
- (2010) Michael P. Manns et al. JOURNAL OF HEPATOLOGY
- Discovery of Vaniprevir (MK-7009), a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor
- (2010) John A. McCauley et al. JOURNAL OF MEDICINAL CHEMISTRY
- Evaluating the Substrate-Envelope Hypothesis: Structural Analysis of Novel HIV-1 Protease Inhibitors Designed To Be Robust against Drug Resistance
- (2010) M. N. L. Nalam et al. JOURNAL OF VIROLOGY
- Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
- (2010) Paul Y Kwo et al. LANCET
- Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding
- (2010) K. P. Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
- (2010) L. Rong et al. Science Translational Medicine
- In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor
- (2009) T.-I Lin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease
- (2009) N. J. Liverton et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
- (2009) Christoph Sarrazin et al. GASTROENTEROLOGY
- Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients
- (2009) Simone Susser et al. HEPATOLOGY
- Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)
- (2009) T. L. Kieffer et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- 1056 MK-7009 SIGNIFICANTLY IMPROVES RAPID VIRAL RESPONSE (RVR) IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION
- (2009) M.P. Manns et al. JOURNAL OF HEPATOLOGY
- The global burden of hepatitis C
- (2009) Daniel Lavanchy LIVER INTERNATIONAL
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
- (2009) Dongliang Ge et al. NATURE
- Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
- (2009) Christophe Hézode et al. NEW ENGLAND JOURNAL OF MEDICINE
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
- (2009) John G. McHutchison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)
- (2008) S. D. Seiwert et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started